High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

Uveal melanoma (UM) is the most prevalent cancer of the eye in adults, driven by activating mutation of GNAQ/GNA11; however, there are limited therapies against UM and metastatic UM (mUM). Here, we perform a high-throughput chemogenetic drug screen in GNAQ-mutant UM contrasted with BRAF-mutant cutan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports. Medicine 2023-11, Vol.4 (11), p.101244, Article 101244
Hauptverfasser:	Arang, Nadia, Lubrano, Simone, Ceribelli, Michele, Rigiracciolo, Damiano C, Saddawi-Konefka, Robert, Faraji, Farhoud, Ramirez, Sydney I, Kim, Daehwan, Tosto, Frances A, Stevenson, Erica, Zhou, Yuan, Wang, Zhiyong, Bogomolovas, Julius, Molinolo, Alfredo A, Swaney, Danielle L, Krogan, Nevan J, Yang, Jing, Coma, Silvia, Pachter, Jonathan A, Aplin, Andrew E, Alessi, Dario R, Thomas, Craig J, Gutkind, J Silvio
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Drug Evaluation, Preclinical GTP-Binding Protein alpha Subunits - genetics GTP-Binding Protein alpha Subunits - metabolism GTP-Binding Protein alpha Subunits, Gq-G11 - genetics GTP-Binding Protein alpha Subunits, Gq-G11 - metabolism GTP-Binding Protein alpha Subunits, Gq-G11 - therapeutic use Melanoma - drug therapy Melanoma - genetics Melanoma - pathology Mice Protein Kinase Inhibitors - pharmacology Skin Neoplasms Uveal Neoplasms - drug therapy Uveal Neoplasms - genetics Uveal Neoplasms - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!